AJ Vaccines To Develop Vaccine for COVID-19
“This endeavor reiterates our ambition to serve the global community, not only with existing effective high-quality vaccines, but also with the development of innovative new vaccines to answer the current global challenge of coronavirus COVID-19”, says Dr Tabassum Khan, Chairman to AJ Vaccines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200306005124/en/
Committed to prevent serious disease globally
“The impact of the COVID-19 disease globally is developing by the hour and we are committed to a world free of serious diseases across all generations. Our employees are aware of the current challenges and are dedicated to finding solutions to the COVID-19 challenge with state-of-the-art technology”, says Jesper Helmuth Larsen, CEO AJ Vaccines.
High protection, low risk of side effects
“The main principle of vaccination is to proactively induce a protective immune response by mimicking the natural interaction of infectious pathogens with our immune system. Modern antigen technology allows for the production of vaccines combining high protection with a low reactogenicity and favorable safety profile as compared to some of the more traditional vaccines. Our aim is to combine the best possibly designed antigens in such a way to mimic closely the authentic native structures of the virus. Similar technologies were previously successfully applied in US FDA-approved vaccines. In short, the use of such technology is expected to induce the relevant immune responses and therefore protect against disease with a lower risk for side effects”, concludes Jerome Cabannes, COO AJ Vaccines.
Notes for editors
AJ Vaccines Group based in Copenhagen Denmark develop and manufacture vaccines against serious infectious diseases such as tetanus, diphtheria, tuberculosis, pertussis (whooping cough) and polio. In addition, the Group manufactures Tuberculin for screening and diagnosis of high-risk patients for infection with TB, and BCG Culture (Danish strain 1331) for the standard treatment for intermediate and high-risk non-muscle invasive bladder cancer. Our affiliate office in Malaysia focuses on in-licensing and developing, newer more effective vaccines and diagnostics relevant to the region, such as leptospirosis, influenza and cholera.
The company has some 750 employees and expects to expand its skilled workforce in order to fulfill the ambitious growth plans.
See more at: http://www.ajvaccines.com/
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PI-WORKS24.11.2020 06:02:12 CET | Press release
beCloud Selects P.I. Works to Drive Automation of its Nationwide Multi-Operator and Multi-Vendor LTE Network
CA-NEXON-AMERICA24.11.2020 04:02:11 CET | Press release
Global Superstars BTS Team Up With Iconic MapleStory Games in Brand New Collaboration
WI-SHINE-MEDICAL23.11.2020 20:02:11 CET | Press release
Von Gahlen Building Major Component of SHINE’s One-of-a-Kind Isotope Plant
CA-GRAI-MATTER-LABS23.11.2020 20:02:11 CET | Press release
GrAI Matter Labs Raises $14M to Bring Fastest AI per Watt to Every Device on the Edge
IMMERVISION23.11.2020 17:03:08 CET | Press release
Defense Innovation Unit (DIU) Selects Immervision InnovationLab to Develop a Computer Vision Wide Angle Camera for the Blue UAS Framework Project
CO-MPEG-LA-LLC23.11.2020 15:02:22 CET | Press release
Hisense Sued for Infringement of AVC Essential Patents
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom